Naftifine: Indication, Dosage, Side Effect, Precaution

Generic Medicine Info Patient Medicine Information

This information is not country-specific. Please refer to the Malaysia prescribing information.

Generic Medicine Info

Indications and Dosage

Topical/Cutaneous
Tinea corporis, Tinea cruris

Adult: Apply to the affected area(s) and surrounding skin as 1% cream once daily or as 1% gel bid for up to 4 weeks. As 2% cream: Apply a thin layer once daily to the affected area(s) plus ¹/₂ inch margin to healthy surrounding skin for 2 weeks.
Child: As 2% cream: Tinea corporis: ≥2 years Same as adult dose. Tinea cruris: ≥12 years Same as adult dose.

Topical/Cutaneous
Tinea pedis

Adult: Apply to the affected area(s) and surrounding skin as 1% cream once daily or as 1% gel bid for up to 4 weeks As 2% cream/gel: Apply a thin layer to the affected area(s) plus ¹/₂ inch margin of healthy surrounding skin once daily for 2 weeks.
Child: As 2% gel/cream: ≥12 years Same as adult dose.

Contraindications

Hypersensitivity.

Special Precautions

Pregnancy and lactation.

Adverse Reactions

Significant: Irritation, sensitivity.
General disorders and administration site conditions: Application site reactions.
Skin and subcutaneous tissue disorders: Burning, stinging sensation of the skin; dryness, erythema, itching.

Pregnancy Category (US FDA)

Topical: B

Monitoring Parameters

Perform culture and susceptibility tests or confirm diagnosis via direct microscopic examination of a KOH mounting of infected tissue; consult local institutional recommendations before treatment initiation due to antifungal resistance risks. Monitor for signs of application site reactions (e.g. exfoliation, erythema, dermatitis).

Action

Description:
Mechanism of Action: Naftifine is a synthetic allylamine with fungistatic and fungicidal activity. It inhibits squalene 2, 3-epoxidase which causes a decrease in ergosterol synthesis and consequently an increase in squalene cells.
Pharmacokinetics:
Absorption: Systemically absorbed after topical application.
Excretion: Via urine and faeces (as unchanged drug and metabolites). Elimination half-life: 2-3 days.

Chemical Structure

Storage

Store between 20-25°C. Storage recommendations may vary among individual products. Refer to specific product guidelines.

MIMS Class

Topical Antifungals & Antiparasites

ATC Classification

D01AE22 - naftifine ; Belongs to the class of other antifungals for topical use.

References

Anon. Naftifine. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 05/03/2021.

Anon. Naftifine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 05/03/2021.

Buckingham R (ed). Naftifine Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 05/03/2021.

Exoderil Cream (P&G Health Austria GmbH & Co. OG). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 05/03/2021.

Naftifine Hydrochloride Cream (Tolmar, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 05/03/2021.

Naftifine Hydrochloride Gel (Tolmar, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 05/03/2021.

Naftin Cream (Merz Pharmaceuticals). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 05/03/2021.

Naftin Gel (Sebela Pharmaceuticals Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 08/03/2021.

Disclaimer: This information is independently developed by MIMS based on Naftifine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com